921 / 1266
PAge74
1/25/2016 |
Author
Division
a
Olaf Witt
SIOP LGG 201X
Studiendesign
Why Vinblastine?
•
Single agent activity
Bouffet et al., JCO 2012, Phase II, n=51, 5 year PFS 42%
•
Low neurotoxicity
=> OPG/Thalamic tumors
•
Anti-angiogenic activity at low doses
Klement et al., JCI 2000; Vacca et al., Blood 2004
•
Phase I Carbo+VBL
Jakacki et al., 2011, Carbo +VBL at 400mg/m2/d + VBL 4mg/m2/d
1 PR=>CR, 6 OR (1PR), 11 SD, 3 PD (total 21)
7/9 OPG: improvement of vision